Clinical and microbiological characterization of KPC-producing Klebsiella pneumoniae infections in Brazil

ABSTRACT

In 2008 isolates of KPC-producing Klebsiella pneumoniae (KPC-KPN) were detected for the first time at Hospital Heliópolis, São Paulo, Brazil. The aim of this study was to characterize the clinical and microbiological outcomes of infections caused by KPC-KPN. A historical cohort of patients from whom KPC-KPN strains were isolated was performed. Isolates were identified as resistant to ertapenem by automated broth microdilution system and screened as carbapenemase producers by the modified Hodge test. The beta-lactamase resistance gene blaKPC was detected by PCR. The genetic relatedness of isolates was determined by PFGE. The study provides early clinical experience in treating KPC-KPN infections in a Brazilian tertiary center.

Keyword: Klebsiella pneumonia; KPC; hospital infection; carbapenemase.

INTRODUCTION

Carbapenems such as imipenem and meropenem are recommended as first-line therapy for severe infections caused by Enterobacteriaceae producing extended spectrum β-lactamas (ESBLs). The increasing incidence of Klebsiella pneumoniae carbapenemase (KPC)-producing strains worldwide has posed a challenge for diagnosing and treating such infections since these isolates might be phenotypically detected as susceptible to carbapenems. In addition, therapeutic options for the treatment of these infections are basically restricted to tigecycline and polymyxins. However, the clinical use of these antimicrobials has been limited due to their pharmacokinetics properties and toxicity. Moreover, no new antibiotics against these multidrug-resistant (MDR) organisms are in advanced stages of clinical development (Table 1).

KPC-producing Klebsiella pneumoniae (KPC-KPN) was first isolated in North Carolina in 1996. It remained infrequently isolated until 2001, when several outbreaks occurred in hospitals located in the New York region. KPC-KPN has spread over time in many countries around the world, and have been frequently isolated from Israel, China and Greece. In South America, the first detection of a KPC-2-producing Klebsiella pneumoniae isolates occurred in Colombia in 2006. Although the KPC-KPN isolates were detected in the cities of Recife and Rio de Janeiro, in 2006 and 2007, respectively, an early dissemination of KPC-KPN in the Brazilian territory was reported by Pavez et al. These authors showed that KPC-KPN was detected in the city of São Paulo, in 2005. In 2008, we detected for the first time isolates of K. pneumoniae resistant to ertapenem in the Hospital Heliópolis, a teaching tertiary hospital located in the city of São Paulo, Brazil. These isolates were identified as resistant to ertapenem by automated broth microdilution system (MicroScan; Siemens) and screened as carbapenemase producers by the modified Hodge test as recommended by the Clinical Laboratory Standards Institute (CLSI, 2009). These isolates were referred to Laboratório Alerta, Division of Infectious Diseases, UNIFESP/EPM, where antimicrobial susceptibility testing, KPC production and genetic relatedness among KPC-KPN isolates were performed by CLSI agar dilution, PCR and PFGE, respectively.

We sought to study the clinical and microbiological outcomes of the KPC-KPN infections by performing a historical cohort of patients from whom KPC-KPN strains had been isolated. Medical records of colonized/infected KPC-KPN patients were reviewed. Success or failure of treatment was determined by clinical response. This study was approved by the institutional review board.
Six KPC-KPN were isolated from six distinct patients between May 2008 and February 2009. Patient’s age ranged from 54 to 89 years. Most patients (66.6%) had been hospitalized for at least three weeks before KPC-KPN isolation. Beta-lactams (50%) were the most common antimicrobial therapy prior to KPC-KPN isolation, with a single patient receiving carbapenem therapy.

The susceptibility profile of the KPC-KPN isolates is shown in Table 2. Of the six KPC-KPN cultured from patients, three (50%) were originally reported as imipenem susceptible. Phenotypic detection of carbapenemase production was reported only three days later. All KPC-KPN exhibited resistance to beta-lactam/beta-lactamase inhibitor combination, carbapenems, and third-generation cefalosporins, except for a single isolate that showed susceptibility to ceftazidime and ceftriaxone. In contrast, all KPC-KPN isolates were susceptible to amikacin. No full resistance to tigecycline or polymyxin B was observed among the CRKP tested.

**Table 1. Demographic characteristics and clinical outcomes of patients with KPC-KPN isolated**

<table>
<thead>
<tr>
<th>Patient number</th>
<th>PFGE patterns</th>
<th>Sex/age (years)</th>
<th>Underlying condition</th>
<th>Comorbid condition</th>
<th>LOS (days)</th>
<th>Previous antibiotics, (days)</th>
<th>Source infection</th>
<th>Antibiotic treatment</th>
<th>Leukocyte urine/urinary catheter removal (Yes/No)</th>
<th>Clinical signs of sepsis</th>
<th>Clinical outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>A</td>
<td>M/46</td>
<td>Acute abdominal perforation</td>
<td></td>
<td>20</td>
<td>Ceftriaxone (14)</td>
<td>Blood</td>
<td>Polymyxin B</td>
<td>_</td>
<td>Yes</td>
<td>Death, related to infection</td>
</tr>
<tr>
<td>2</td>
<td>B</td>
<td>F/69</td>
<td>CNS tumor</td>
<td>Cancer</td>
<td>23</td>
<td>-</td>
<td>Urine</td>
<td>Ciprofloxacin</td>
<td>&gt; 10³</td>
<td>No</td>
<td>Cured</td>
</tr>
<tr>
<td>3</td>
<td>A</td>
<td>F/54</td>
<td>UTI</td>
<td>CHF, COPD, RF</td>
<td>3</td>
<td>-</td>
<td>Urine</td>
<td>Ceftriaxone</td>
<td>6 x 10⁷</td>
<td>Yes</td>
<td>Death, not related to infection</td>
</tr>
<tr>
<td>4</td>
<td>C</td>
<td>M/59</td>
<td>CNS cancer</td>
<td>Cancer, steroids</td>
<td>78</td>
<td>Meropenem (49)</td>
<td>CNS catheter</td>
<td>Meropenem</td>
<td>-</td>
<td>Yes</td>
<td>Death not related to infection</td>
</tr>
<tr>
<td>5</td>
<td>A</td>
<td>M/89</td>
<td>Infected foot ulcer</td>
<td>Chronic arterial insufficiency</td>
<td>33</td>
<td>Ciprofloxacin (21)</td>
<td>Urine</td>
<td>Cefepime</td>
<td>4 x 10⁷</td>
<td>No</td>
<td>Cured</td>
</tr>
<tr>
<td>6</td>
<td>A</td>
<td>F/72</td>
<td>CNS tumor</td>
<td>Cancer steroids</td>
<td>18</td>
<td>Cefepime (12)</td>
<td>Urine</td>
<td>Cefepime</td>
<td>16 x 10⁴</td>
<td>No</td>
<td>Cured</td>
</tr>
</tbody>
</table>

M, male; F, female; CHF, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; LOS, length of stay prior to culture positive; RF, renal failure; UTI, urinary tract infection.

**Table 2. MIC of selected antimicrobial agents for KPC-KPN strains**

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amikacin</td>
<td>8</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
<td>&lt; 4</td>
<td>8</td>
</tr>
<tr>
<td>Polymyxin B</td>
<td>&lt; 0.5</td>
<td>&lt; 0.5</td>
<td>&lt; 0.5</td>
<td>4</td>
<td>&lt; 0.5</td>
<td>2</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>&gt; 2</td>
<td>&lt; 0.25</td>
<td>&gt; 2</td>
<td>&gt; 2</td>
<td>&gt; 2</td>
<td>&gt; 2</td>
</tr>
<tr>
<td>Levofloxacin</td>
<td>&gt; 4</td>
<td>&gt; 4</td>
<td>&gt; 4</td>
<td>&gt; 4</td>
<td>&gt; 4</td>
<td>&gt; 4</td>
</tr>
<tr>
<td>Aztreonam</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
</tr>
<tr>
<td>Tigecycline</td>
<td>1</td>
<td>0.5</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>&gt; 32</td>
<td>8</td>
<td>&gt; 32</td>
<td>&gt; 32</td>
<td>&gt; 32</td>
<td>&gt; 32</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>&gt; 16</td>
<td>8</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
</tr>
<tr>
<td>Cefepime</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
<td>&gt; 16</td>
</tr>
<tr>
<td>Imipenem</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
</tr>
<tr>
<td>Meropenem</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
<td>&gt; 8</td>
</tr>
<tr>
<td>Piperacillin/Tazobactam</td>
<td>&gt; 64/4</td>
<td>&gt; 64/4</td>
<td>&gt; 64/4</td>
<td>&gt; 64/4</td>
<td>&gt; 64/4</td>
<td>&gt; 64/4</td>
</tr>
</tbody>
</table>

Characterization of KPC in Brazil
Among the six KPC-KPN isolates, three PFGE patterns were observed and denominated patterns A, B and C. Four isolates were clonally related (pattern A), while two isolates were not, with one of them isolated from a patient who had been hospitalized in a different institution.

**CASE REPORTS**

**Clinical case 1**
In April 2008, a 46 year-old man was submitted to an exploratory laparotomy due to perforated peptic ulcer and sent to the ICU for recovery. The patient had dehiscence of the surgical wound and was reoperated. After receiving ceftriaxone 2 g twice daily, and metronidazol 500 mg three times a day for 14 days, the patient developed *Klebsiella pneumoniae* bloodstream infection associated with septic shock, and antibiotic was changed for piperacillin–tazobactam. This pathogen was resistant to ertapenem, but susceptible to imipenem by the MicroScan. This finding drew our attention to the possibility of a KPC-KPN. Three days after the isolation of KPC-KPN, the Hodge’s test confirmed the production of a carbapenemase, and polymyxin B 15 000 UI/kg/day was initiated. No clinical response was observed and the patient deceased nine days later.

**Clinical case 2**
In May 2008, a 69 year-old woman was admitted for an elective surgical resection of a central nervous system (CNS) tumor. In the post-operative, the patient was admitted in the neurosurgery ICU, and remained in this unit for 11 days. After this period, the patient was sent to the neurosurgery ward, and five days later, she presented an urosepsis. The patient was not receiving any antibiotics and intravenous ciprofloxacin 400 mg twice daily was initiated. Urine culture confirmed the pure growth of *K. pneumoniae* (> 10⁶ colony unit forms), susceptible to ciprofloxacin but resistant to ertapenem. The urethral catheter was removed and ciprofloxacin therapy was maintained for seven days. The patient showed a complete recovery and was discharged from the hospital 38 days later.

**Clinical case 3**
A 54 year-old woman was admitted to the ICU with signals and symptoms of septic shock due to a urinary tract infection. She was started on ventilatory support and noradrenaline and ceftriaxone 1 g twice daily were prescribed. The patient had a history of being hospitalized in another hospital 15 days before the current clinical manifestation. After three days, a *K. pneumoniae* (> 10⁶ UFC) resistant to ertapenem, imipenem and meropenem was isolated from the urine culture. At that time, the patient was asymptomatic and not dependent on vasopressive drugs or mechanical ventilation. Since the patient had an excellent clinical response, ceftriaxone treatment was completed in the internal medicine ward. However, the patient died due to cardiac and respiratory failure after 27 days of hospitalization.

**Clinical case 4**
In June 2008, a 59 year-old man was admitted to hospital for a CNS tumor resection. In the 5th PO day, the patient had a surgical complication with a secondary bowel perforation by the ventriculo-peritoneal shunt. A fecal peritonitis was diagnosed and the patient was submitted to abdominal surgery. The ventriculo-peritoneal shunt was removed and an external ventricular shunt (EVS) was placed on. A *K. pneumoniae* secondary meningitis occurred three days after the EVS placement. This pathogen was susceptible to broad-spectrum cephalosporins and cefepime 2 g three times a day was empirically prescribed and kept until the 11th day of therapy, when an *Acinetobacter baumannii* was isolated from the spinal fluid during a routine culture. The EVS was replaced and cefepime therapy was stopped. Meropenem (2 g three times a day) was initiated and despite the isolation of *A. baumannii*, vancomycin 1 g twice daily was added to the antimicrobial regimen because the patient had undergone many surgical procedures during his hospitalization. After 49 days of vancomycin and meropenem therapy, a *K. pneumoniae* resistant to imipenem, meropenem and ertapenem was recovered from the CNS device. The neurosurgery team considered the *K. pneumoniae* as a contaminant because it was not recovered from his cerebrospinal fluid. The antimicrobial therapy was not modified, and the patient died five months later due to a respiratory infection.

**Clinical case 5**
In August 2008, an 89 year-old male with chronic arterial insufficiency was admitted to the vascular surgery ward for treatment of an infected right foot ulcer. The patient was treated with ciprofloxacin 400 mg twice daily, and submitted to surgical treatment due to common iliac artery occlusion. In the 32nd day of hospitalization, the patient had signals and symptoms suggestive of urinary tract infection; ciprofloxacin therapy was replaced by cefepime 2 g twice daily. Three days later, the results of urine culture became available and showed the growth of a KPC-KPN (> 10⁶ CFU/mL). Since the patient had become asymptomatic, cefepime therapy was kept and the patient was discharged from the hospital after completing seven days of therapy.

**Clinical case 6**
A 72 year-old female patient with previous history of CNS tumor was taken unconscious to the emergency unit. Despite of the patient’s option for not receiving surgical treatment, tumor resection was performed with the family consent. The patient was admitted to the ICU, where she received prolonged mechanical ventilation and urinary catheterization. She received antibiotic therapy with cefepime 2 g twice daily due to a tracheobronchitis. She was extubated four days later due to rapid clinical improvement. A urine culture was collected before urinary catheter removal in spite of no
infection evidence. A KPC-KPN (> 10^5 CFU) was recovered from urine and considered just a colonizer since the patient had no clinical manifestations of urinary tract infection. The patient did not receive any antibiotics and was discharged one day later from our hospital.

**DISCUSSION**

We described microbiological features and clinical outcomes of six patients from whom KPC-KPN strains were firstly isolated in our institution. KPC-KPN represents a real challenge, since microbiological detection of this resistant phenotype might be tricky. In addition, a few therapeutic options are available for treatment of such infections, and are basically restricted to polymyxins and tigecycline.3

In our study, a urinary catheter was placed in all four patients from whom KPC-KPN strains were isolated from urine. All of these patients also showed elevated leucocyte count in urine. It has been reported that the risk of developing bacteriuria increased by 5% for each additional day of urinary catheterization and 50% of the patients had acquired bacteriuria by the tenth day of catheterization.13 The distinction between urinary colonization and infection is difficult because many times patients hospitalized in ICUs are sedated or unconscious and are not able to provide clinical information about his/her symptoms. Just one of the four patients colonized/infected by KPC-KPN strains was conscious and confirmed the symptoms suggestive of infection. This patient was successfully treated with ciprofloxacin guided by the antimicrobial susceptibility testing results. Two other patients were also successfully treated with broad-spectrum cephalosporins in spite of no reliable in vitro activity of these agents against KPC-KPN strains.14 We believe that these patients were infected by KPC-KPN strains because there was a resolution of clinical symptoms after introduction of the antimicrobial regimen. The successful clinical outcomes experienced by the patients treated with beta-lactam antibiotics have been previously reported15 but the degree to which the antibiotic treatment contributed to these outcomes is difficult to ascertain. Good clinical response to antibiotics with no in vitro activity might have been achieved by the increased antimicrobial concentration in the urine. In addition, most of the patients had the urine catheter removed, and this is of crucial importance for a successful outcome.14 Antimicrobial treatment was not modified because the Hodge test's final result was available only after the third day of beta-lactam therapy, when the patients have already had a favorable clinical outcome.

The patient reported in the clinical case 1 had a severe KPC-KPN infection with a fatal outcome that could be attributed to an inadequate empiric therapy with piperacillin/tazobactam, a delay in the introduction of polymyxin as well as the low dose regimen of the later agent. Therapy was only changed three days after the isolation of Gram-negative bacilli in the blood culture.

Currently, the therapeutic options for highly resistant, carbapenemase-producing organisms are limited. Polymyxin B and tigecycline both seem to have reliable efficacy.16 Polymyxin is a compound developed decades ago and previously abandoned due to its toxicity. It has been resurrected because it is the only available therapeutic option for treatment of some pan-resistant Gram-negatives infections.16 Tigecycline is a novel extended-spectrum minocycline derivative, approved by the American Food and Drug Administration (FDA) for treatment of complicated skin, intra-abdominal infections and community-acquired pneumonia, but not for bloodstream and/or urinary infections.17 Although KPC-producing isolates show higher tigecycline MICs than those of wild type bacterial isolates, tigecycline possesses potent in vitro activity against these pathogens.18 Clinical data also supports efficacy of tigecycline for treating MDR Gram-negative infections in body sites where tigecycline does not reach therapeutic levels when habitual dosage regimens are prescribed.19 In these situations, the use of combined therapy and/or higher doses of tigecycline are critical for maximal therapeutic effectiveness.20 This would be specially useful in patients with infections due to pathogens with reduced susceptibility to polymyxin, such as those presented in the clinical cases 4 and 6.

Although our study describes a small number of heterogeneous patients at a single institution, our findings should provide early clinical experience in treating KPC-KPN infections in Brazil. Our results also underscore the importance of implementation of strict infection control measures to limit their dissemination, since four isolates were clonally related suggesting a patient-to-patient transmission in our institution.

**REFERENCES**

7. Wei ZQ, Du XX, Yu YS et al. Plasmid-mediated KPC-2 in a 
*Klebsiella pneumoniae* isolate from China. Antimicrob Agents 

8. Cuzon G, Naas T, Demachy MC et al. Plasmid-mediated car-
banem-hydrolyzing β-lactamase KPC in *Klebsiella pneumo-
52:796-97.

9. Villegas MV, Lolans K, Correa A et al. First detection of the 
plasmid-mediated class A carbapenemase KPC-2 in clinical 
isolates of *Klebsiella pneumoniae* from South America. Anti-

10. Monteiro J, Santos AF, Asensi MD et al. First report of KPC-
2-producing-*Klebsiella pneumoniae* in Brazil. Antimicrob 

ing β-lactamase KPC-2 in *Klebsiella pneumoniae* isolated in Rio 

12. Pavez M, Neves P, Dropa M et al. Emergence of carbapenem-
resistant Escherichia coli producing CMY-2-type AmpC beta-

Factors predisposing to bacteriuria during indwelling urethral 

14. Stephen G Jenkins; David P. Calfee, Outcomes of Carbapen-
em-Resistant *Klebsiella pneumoniae* Infection and the Impact 
of Antimicrobial and Adjunctive Therapies. Infect Control 

15. Weisenberga SA, Morganc DJ, Espinal-Witter R, Laroneb 
D.H. Clinical outcomes of patients with *Klebsiella pneumo-
niae* carbapenemase-producing *K. pneumoniae* after treat-
ment with imipenem or meropenem. Diagnostic Microbi-
ology and Infectious Disease 2009; 64:233-23

16. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins 

predictor of clinical efficacy. Clin Microbiol Infect. 2007; 

18. Castanheira M, Sader HS, Deshpande LM, Fritsche TR, 
Jones RN. Antimicrobial activities of tigecycline and other 
broad-spectrum antimicrobials tested against serine car-
apenemase- and metallo-beta-lactamase-producing en-
terobacteriaceae: Report from the SENTRY antimicrobial 
surveillance program. Antimicrobial Agents and Chemo-
therapy 2008; 52(2):570-573.

19. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edel-
stein PH, Lautenbach E. Clinical and Microbiological 
Outcomes of Serious Infections with Multidrug-Resistant 
Gram-Negative Organisms Treated with Tigecycline. Clini-
cal Infectious Diseases 2008; 46:567-70.

20. Nicasio AM, Crandon JL, Nicolau DP. *In vivo* Pharmacody-
namic Profile of Tigecycline against Phenotypically Di-
verse Escherichia coli and *Klebsiella pneumoniae* Isolates. 